$PLUR News

Pluri Announces Completion Of Development And U.S. Cosmetic Product Listings For Two Flagship Regenerative Aesthetic Products, Regenativo+ And Placento+, Clearing Way For U.S. Commercial Launch

Plurilock Announces Payment of Debenture Interest

Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

Pluri Signs Agreement With Beneficiary Owned By Chairman Alejandro Weinstein For Additional $2.5M Investment In Co.

Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent

Pluri Subsidiary Puri Biotech Secures Patent Covering 3D Immune Cell Expansion Tech

Pluri: Fiscal Q2 Earnings Snapshot

Pluri Q2 EPS $(0.71) Misses $(0.65) Estimate, Sales $198.000K Miss $638.000K Estimate

Pluri showcases cell expansion platform as Resbiomed program advances

Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials

Pluri Completes First Phase Of Its Program With Resbiomed Technologies OOD Over Placenta-Derived Processing, Bioprocessing Capabilities

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Pluri Expands Manufacturing Agreement With Remedy Cell, Advances Clinical-Grade Production

12 Health Care Stocks Moving In Monday's Pre-Market Session

A US$3.4m Market Cap Boost Pleasing ToPluri Insiders

Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment

Pluri Appoints Alejandro Weinstein As Chairman

Pluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the Year

Pluri: Fiscal Q1 Earnings Snapshot

Pluri Q1 EPS $(0.65) Beats $(0.74) Estimate, Sales $316.000K Miss $638.000K Estimate